Fundz

Debiopharm

Switzerland · Biotechnology, Health Care, Therapeutics

Debiopharm is a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases. Debiopharm is focused on developing innovative therapeutic agents to outsmart hard-to-treat cancers and has a portfolio of carefully selected targets with first-in-class or best-in-class potential.

Key facts

Headquarters
Switzerland
Employees
494
Industries
Biotechnology, Health Care, Therapeutics
Website
www.debiopharm.com
LinkedIn
Company page

Recent activity at Debiopharm

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Debiopharm funding history

DateRoundAmount
Nov 2024Funding Round$5.8M

Leadership

  • Bertrand Ducrey, Chief Executive Officer
  • Angela Zubel, Chief Development Officer

Verified email and direct lines for Debiopharm’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Debiopharm in the news

Companies similar to Debiopharm

About Debiopharm: questions and answers

What does Debiopharm do?

Debiopharm is a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases. Debiopharm is focused on developing innovative therapeutic agents to outsmart hard-to-treat cancers and has a portfolio of carefully selected targets with first-in-class or best-in-class potential.

Where is Debiopharm headquartered?

Debiopharm is headquartered in Switzerland.

How many employees does Debiopharm have?

Debiopharm has about 494 employees.

Has Debiopharm raised funding?

Yes. Fundz has recorded 1 funding event for Debiopharm. The most recent, Funding Round of $5.8M, was in Nov 2024.

Who leads Debiopharm?

Bertrand Ducrey is a Chief Executive Officer at Debiopharm.

What is the latest news on Debiopharm?

On Jan 11, 2026, Debiopharm Partners with Genialis to Utilize AI Software for Biomarker Discovery.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Debiopharm across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.